novartis_rm_logo_pos_rgb.png
cosentyx logo r.jpeg
xolair logo.jpeg
NV110-21 NVS Nurse Roadshow_logo_full colour_RGB.png
Spot_Light_Background.png

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited and is intended for UK healthcare professionals only.

UK | November 2021 | 165784

By clicking the below link (www.mhra.gov.UK/yellowcard) you will leave the Novartis-associated website. This link will take you to a website to which our privacy policy does not apply. You are solely responsible for your interactions with that website.

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.UK/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.

Cosentyx (secukinumab) Indications: Treatment of moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy.

Xolair (omalizumab) Indication: Xolair is indicated as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment.